Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5

Ding, Gangqiang; Zeng, Yanli; Yang, Dong; Zhang, Can; Mao, Chongshan; Xiao, Erhui; Yi, Kang; Shang, Jia

doi:10.1186/s12935-021-01847-6

Cited by 13 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with above, Ding G etc. concluded that knock out of DDX11-AS1 or upregulation of miR-34a-3p was key to inhibiting hepatocellular carcinoma cells growth 40 . It has been demonstrated that MIR34AHG might provide new insight to identify potential diagnostic biomarkers and predict the prognosis of lung adenocarcinoma 41,42 .…”

Section: Discussionmentioning

confidence: 99%

A New Establishment of Cuproptosis-Related Long Non-Coding RNA Signature to Predict Prognosis in Head and Neck Squamous cell Carcinomas

wang

Gao

Xue

et al. 2022

Preprint

View full text Add to dashboard Cite

Background Cuproptosis is a novel type of programmed cell death which plays an important role in the development and progression of cancer. However, there is a limited amount of research on cuproptosis-associated long non-coding RNAs (lncRNAs) in head and neck squamous cell carcinomas (HNSCCs). This study aimed to investigate the predictive value of cuproptosis-related lncRNA signature for HNSCC prognosis. Method Transcriptomic and clinical data of HNSCC patients were obtained from the Cancer Genome Atlas (TCGA). We established a cuproptosis-related lncRNA signature and then constructed a hybrid nomogram based on risk scores and clinical factors. We also performed differential expression genes (DEGs) function, immune cells infiltration, immune checkpoint analysis based on cuproptosis-associated lncRNA signature. Results A signature of 27 cuproptosis-related lncRNAs was performed and the prognosis of patients at high risk is worse compared with patients at low risk based on above signature. A nomogram which integrated risk scores and clinical features also showed favorable predictive power. Furthermore, DEGs in high or low risk group were mainly enriched in immune-related pathways. Anti-tumor immune cells and immune checkpoints were mainly enriched in low risk group compared with high risk group. Conclusion Cuproptosis-related lncRNAs could be regarded as independent indicators for HNSCC prognosis which might be effective targets for HNSCC therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A New Establishment of Cuproptosis-Related Long Non-Coding RNA Signature to Predict Prognosis in Head and Neck Squamous cell Carcinomas

wang

Gao

Xue

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…DDX11-AS1 is a newly discovered LncRNA, which is abnormally highly expressed in multiple malignant tumors [ 57 ], such as HCC, colorectal cancer, and gastric cancer. DDX11-AS1 plays its carcinogenic role by regulating the expression of related genes directly or indirectly, with the following examples given: DDX11-AS1 can bind to HNRNPC to promote the proliferation and migration of glioma cells [ 58 ] and silencing DDX11-AS1 can inhibit the growth of HCC cells by upregulating TRAF5 [ 59 ]. These results have suggested that DDX11-AS1 may play a significant regulatory role in tumors.…”

Section: Discussionmentioning

confidence: 99%

The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma

Song

Zheng

2023

Journal of Oncology

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC), ranking as one of the most common malignant tumors, is one of the leading causes of cancer death, with a poor prognosis. Cuproptosis, a novel programmed cell death modality that has just been confirmed recently, may play an important role in HCC prognosis. Long noncoding RNA (LncRNA) is a key participant in tumorigenesis and immune responses. It may be of great significance to predict HCC based on cuproptosis genes and their related LncRNA. Methods. The sample data on HCC patients were obtained from The Cancer Genome Atlas (TCGA) database. Combined with cuproptosis-related genes collected from the literature search, expression analysis was carried out to find cuproptosis genes and their related LncRNAs significantly expressed in HCC. The prognostic model was constructed by least absolute shrinkage and selection operator (LASSO) regression and multivariate Cox regression. The feasibility of these signature LncRNAs used for the evaluation of the overall survival rate in HCC patients as independent factors was investigated. The expression profile of cuproptosis, immune cell infiltration, and the status of somatic mutation were analyzed and compared. Results. A prognostic model of HCC consisting of seven cuproptosis gene-related LncRNA signatures was constructed. Multiple verification methods have showed that this model can accurately predict the prognosis of HCC patients. It was showed that the classified high-risk group under the risk score of this model had worse survival status, more significant expression of the immune function, and higher mutation frequency. During the analysis, the cuproptosis gene CDKN2A was found to be most closely related to LncRNA DDX11-AS1 in the expression profile of HCC patients. Conclusion. The cuproptosis-related signature LncRNA in HCC was identified, on the basis of which a model was constructed, and it was verified that it can be used to predict the prognosis of HCC patients. The potential role of these cuproptosis-related signature LncRNAs as new targets for disease therapy in antagonizing HCC development was discussed.

show abstract

“…This study for the first time identified that LIN28A was a target of DDX11-AS1 and was involved in DDX11-AS1-mediated drug resistance in BRCA. It has been found that the main mechanism that DDX11-AS1 promotes cancer progression was to eliminate the inhibitory effect of endogenous miRNAs [30][31][32][33]. Few studies have also found that DDX11-AS1 can exert biological functions by interacting with specific proteins.…”

Section: Discussionmentioning

confidence: 99%

LncRNA DDX11-AS1 Promotes Chemoresistance through LIN28A-Mediated ATG12 mRNA Stabilization in Breast Cancer

Si¹,

Zhang

Li³

et al. 2022

Pharmacology

View full text Add to dashboard Cite

Introduction: During breast cancer chemotherapy, the chemoresistance that frequently accompanies the treatment has become a big challenge. Long noncoding RNAs (LncRNAs) have been related to the development of chemoresistance in multiple cancer types. LncRNA DDX11-AS1 has shown a carcinogenic role in lung and colorectal cancer and was reported to enhance oxaliplatin resistance in gastric cancer and Taxol insensitivity in esophageal cancer. But its role in breast cancer chemotherapy drug resistance remains unknown. This study aimed to investigate the function and mechanism of lncRNA DDX11-AS1 in breast cancer chemoresistance. Methods: The relationship between DDX11-AS1 and adriamycin (ADR) resistance was confirmed by qPCR, cell viability tests, and survival analysis. Then, RNA immunoprecipitation was conducted to evaluate the interaction between DDX11-AS1 and RNA-binding protein LIN28A. The regulation effect of LIN28A on autophagy-related genes ATG7 or ATG12 was detected by RNA stability assay and Western blot. Their correlation analysis was evaluated in GEO datasets and further validated by immunohistochemical results. The clinical significance of DDX11-AS1, ATG7, or ATG12 was evaluated by Kaplan-Meier Plotter analysis. Results: Here, we reported DDX11-AS1 was significantly upregulated in chemoresistant breast cancer cells and overexpression of DDX11-AS1 promoted ADR resistance in breast cancer. LIN28A could interact with DDX11-AS1 and was involved in DDX11-AS1-mediated ADR resistance. Interfering with LIN28A reversed DDX11-AS1-induced ADR resistance. LIN28A could increase the protein level of ATG7 and ATG12 by increasing their mRNA stability. Survival analysis showed that ATG12 expression level was negatively correlated with the prognosis of breast cancer patients. Conclusion: This study clarifies the role of DDX11-AS1 in breast cancer chemoresistance and revealed a new mechanism, that is, interacting with LIN28A to stabilize ATG7 and ATG12 and jointly promote chemorefractory. These findings warrant further in vivo investigations to study DDX11-AS1 as a potential target to overcome chemoresistance.

show abstract

Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5

Cited by 13 publications

References 31 publications

A New Establishment of Cuproptosis-Related Long Non-Coding RNA Signature to Predict Prognosis in Head and Neck Squamous cell Carcinomas

A New Establishment of Cuproptosis-Related Long Non-Coding RNA Signature to Predict Prognosis in Head and Neck Squamous cell Carcinomas

The Cuproptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma

LncRNA DDX11-AS1 Promotes Chemoresistance through LIN28A-Mediated ATG12 mRNA Stabilization in Breast Cancer

Contact Info

Product

Resources

About